Massachusetts Financial Services Co. MA Lowers Position in Legend Biotech Corporation Sponsored ADR $LEGN

Massachusetts Financial Services Co. MA trimmed its stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) by 8.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 480,143 shares of the company’s stock after selling 41,668 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Legend Biotech were worth $10,438,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Harbor Capital Advisors Inc. grew its holdings in Legend Biotech by 24.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 30,141 shares of the company’s stock valued at $655,000 after purchasing an additional 5,996 shares during the period. Aberdeen Group plc grew its holdings in Legend Biotech by 62.5% in the fourth quarter. Aberdeen Group plc now owns 29,782 shares of the company’s stock valued at $647,000 after purchasing an additional 11,456 shares during the period. Tempus Wealth Planning LLC grew its holdings in Legend Biotech by 51.3% in the fourth quarter. Tempus Wealth Planning LLC now owns 12,217 shares of the company’s stock valued at $266,000 after purchasing an additional 4,141 shares during the period. Banque Pictet & Cie SA purchased a new stake in Legend Biotech in the fourth quarter valued at approximately $315,000. Finally, SG Americas Securities LLC grew its holdings in Legend Biotech by 6,774.9% in the fourth quarter. SG Americas Securities LLC now owns 371,728 shares of the company’s stock valued at $8,081,000 after purchasing an additional 366,321 shares during the period. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Legend Biotech News Roundup

Here are the key news stories impacting Legend Biotech this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $50 price target (large implied upside vs. the current price), which likely attracted buying interest. Read More.
• Neutral Sentiment: HC Wainwright published forward EPS trajectories showing meaningful improvement into 2027 (examples: Q1 2027 $0.17, Q2 2027 $0.24, Q4 2027 $0.43), supporting a longer-term earnings recovery narrative even as near-term figures were revised. Read More.
• Neutral Sentiment: Coverage pieces and analyst commentaries (Globe and Mail, AmericanBankingNews) are highlighting the company alongside peers, keeping Legend in investor conversations but not introducing new material company-specific catalysts. Read More.
• Negative Sentiment: HC Wainwright trimmed near-term EPS estimates — notably Q2 2026 to $0.03 (from $0.06) and Q3 2026 to $0.07 (from $0.14) — which signals weaker near-term profitability expectations and could cap upside until results or guidance prove otherwise. Read More.

Insiders Place Their Bets

In other Legend Biotech news, CEO Ying Huang sold 9,936 shares of Legend Biotech stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $8.77, for a total transaction of $87,138.72. Following the transaction, the chief executive officer directly owned 247,438 shares of the company’s stock, valued at $2,170,031.26. The trade was a 3.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.02% of the stock is currently owned by company insiders.

Legend Biotech Stock Up 2.7%

Shares of LEGN stock opened at $21.08 on Friday. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of -26.35 and a beta of 0.08. Legend Biotech Corporation Sponsored ADR has a fifty-two week low of $16.24 and a fifty-two week high of $45.30. The firm’s 50 day moving average price is $18.42 and its two-hundred day moving average price is $23.61.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.18. The firm had revenue of $306.30 million for the quarter, compared to analysts’ expectations of $310.21 million. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. Legend Biotech’s revenue was up 64.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.07 earnings per share. On average, equities analysts forecast that Legend Biotech Corporation Sponsored ADR will post -1.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on LEGN. Morgan Stanley lowered their target price on shares of Legend Biotech from $50.00 to $49.00 and set an “overweight” rating for the company in a report on Wednesday, March 11th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Legend Biotech in a report on Wednesday. TD Cowen restated a “hold” rating and issued a $21.00 target price (down from $62.00) on shares of Legend Biotech in a report on Thursday, January 22nd. Royal Bank Of Canada reduced their price target on shares of Legend Biotech from $66.00 to $62.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Finally, Oppenheimer started coverage on shares of Legend Biotech in a research report on Wednesday, January 7th. They set an “outperform” rating and a $75.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Legend Biotech presently has an average rating of “Moderate Buy” and a consensus target price of $58.31.

Legend Biotech Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.